左氧氟沙星预防对儿童急性白血病或造血干细胞移植菌血症的影响:随机临床试验
这项多中心开放标签随机试验纳入624例6月龄至21岁患儿,分急性白血病强化化疗组和造血干细胞移植组,评估左氧氟沙星预防对菌血症的疗效与风险。结果显示急性白血病组菌血症显著降低(21.9% vs 43.4%),移植组无显著降低(11.0% vs 17.3%)。
要点
- 急性白血病强化化疗患儿预防性使用左氧氟沙星可显著降低菌血症风险。
- 造血干细胞移植患儿预防性使用左氧氟沙星未显著降低菌血症风险。
- 两组严重感染、侵袭性真菌病、艰难梭菌腹泻及肌肉骨骼毒性无显著差异。
核心结论
- 急性白血病强化化疗患儿接受左氧氟沙星预防较未预防显著降低菌血症。
- 造血干细胞移植患儿接受左氧氟沙星预防未显著降低菌血症。
研究设计与样本
- 多中心、开放标签、随机临床试验,在美国和加拿大76个中心开展,2011年9月至2016年4月入组,随访至2017年9月。
- 共624例6月龄至21岁患儿,分急性白血病组200例(左氧氟沙星100例 vs 对照100例)和造血干细胞移植组424例(左氧氟沙星210例 vs 对照214例)。
- 急性白血病组预防2个连续化疗周期,移植组预防1次移植过程。
主要发现
- 严重感染、侵袭性真菌病、艰难梭菌相关腹泻、2个月和12个月肌肉骨骼毒性在两组间均无显著差异。
临床怎么用
- 对急性白血病接受强化化疗的患儿,可考虑左氧氟沙星预防以降低菌血症风险。
- 对造血干细胞移植患儿,左氧氟沙星预防未显示显著菌血症获益,决策需权衡。
局限性
- 开放标签设计可能引入偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Bacteremia causes considerable morbidity among children with acute leukemia and those undergoing hematopoietic stem cell transplantation (HSCT). There are limited data on the effect of antibiotic prophylaxis in children. OBJECTIVE: To determine the efficacy and risks of levofloxacin prophylaxis in children receiving intensive chemotherapy for acute leukemia or undergoing HSCT. DESIGN, SETTING, AND PARTICIPANTS: In this multicenter, open-label, randomized trial, patients (6 months-21 years) receiving intensive chemotherapy were enrolled (September 2011-April 2016) in 2 separate groups-acute leukemia, consisting of acute myeloid leukemia or relapsed acute lymphoblastic leukemia, and HSCT recipients-at 76 centers in the United States and Canada, with follow-up completed September 2017. INTERVENTIONS: Patients with acute leukemia were randomized to receive levofloxacin prophylaxis for 2 consecutive cycles of chemotherapy (n = 100) or no prophylaxis (n = 100). Those undergoing HSCT were randomized to receive levofloxacin prophylaxis during 1 HSCT procedure (n = 210) or no prophylaxis (n = 214). MAIN OUTCOMES AND MEASURES: The primary outcome was the occurrence of bacteremia during 2 chemotherapy cycles (acute leukemia) or 1 transplant procedure (HSCT). Secondary outcomes included fever and neutropenia, severe infection, invasive fungal disease, Clostridium difficile-associated diarrhea, and musculoskeletal toxic effects. RESULTS: A total of 624 patients, 200 with acute leukemia (median [interquartile range {IQR}] age, 11 years [6-15 years]; 46% female) and 424 undergoing HSCT (median [IQR] age, 7 years [3-14]; 38% female), were enrolled. Among 195 patients with acute leukemia, the likelihood of bacteremia was significantly lower in the levofloxacin prophylaxis group than in the control group (21.9% vs 43.4%; risk difference, 21.6%; 95% CI, 8.8%-34.4%, P = .001), whereas among 418 patients undergoing HSCT, the risk of bacteremia was not significantly lower in the levofloxacin prophylaxis group (11.0% vs 17.3%; risk difference, 6.3%; 95% CI, 0.3%-13.0%; P = .06). Fever and neutropenia were less common in the levofloxacin group (71.2% vs 82.1%; risk difference, 10.8%; 95% CI, 4.2%-17.5%; P = .002). There were no significant differences in severe infection (3.6% vs 5.9%; risk difference, 2.3%; 95% CI, -1.1% to 5.6%; P = .20), invasive fungal disease (2.9% vs 2.0%; risk difference, -1.0%; 95% CI, -3.4% to 1.5%, P = .41), C difficile-associated diarrhea (2.3% vs 5.2%; risk difference, 2.9%; 95% CI, -0.1% to 5.9%; P = .07), or musculoskeletal toxic effects at 2 months (11.4% vs 16.3%; risk difference, 4.8%; 95% CI, -1.6% to 11.2%; P = .15) or at 12 months (10.1% vs 14.4%; risk difference, 4.3%; 95% CI, -3.4% to 12.0%; P = .28) between the levofloxacin and control groups. CONCLUSIONS AND RELEVANCE: Among children with acute leukemia receiving intensive chemotherapy, receipt of levofloxacin prophylaxis compared with no prophylaxis resulted in a significant reduction in bacteremia. However, there was no significant reduction in bacteremia for levofloxacin prophylaxis among children undergoing HSCT.
引用
- Alexander S, Fisher BT, Gaur AH, et al. Effect of Levofloxacin Prophylaxis on Bacteremia in Children With Acute Leukemia or Undergoing Hematopoietic Stem Cell Transplantation: A Randomized Clinical Trial. JAMA. 2018. PMID: 30208456. doi:10.1001/jama.2018.12512
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。